Because most pre-clinical mouse models of AD involving tau expression overexpress only the 4Rtau protein (Lewis et al., 2000; Ramsden et al., 2005; Yoshiyama et al., 2007), these therapeutics have been successful at this stage. The gene discussed is MAPT; the disease is Alzheimer disease.